Skip to main content Accessibility help
×
Home
  • Print publication year: 2009
  • Online publication date: December 2009

Section 6 - Common medical problems

Related content

Powered by UNSILO

References

1.Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113(6), e85–151.
2. WingoP. A., CalleE. E., McTiernanA. How does breast cancer mortality compare with that of other cancers and cardiovascular diseases at different ages in US women?J Womens Health Gend Based Med 2000; 9, 999–1000.
3. MoscaL., AppelL. J., et al. Evidence-based guidelines for cardiovascular disease prevention in women; AHA scientific statement, consensus panel statement. Circulation 2004; 99, 2480–2484.
4. DawberT. R., KannelW. B., RevotskieN., StokesJ. I., KaganA., GordonT. Some factors associated with the development of coronary heart disease; six years' follow-up experience in the Framingham Study. Am J Public Health 1959; 49, 1349–1356.
5. WilsonP. W. F., D'AgostinoR. B., LevyD., BelangerA. M., SilbershatzH., KannelW. B.Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97, 1837–1847.
6. Rich-EdwardsJ. W., MansonJ. E., HennekensC. H., BuringJ. E.The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332, 1758–1766.
7. BushT. L.The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990; 592, 263–271.
8. MoscaL., MansonJ. E., SutherlandS. E., et al. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96, 2468–2482.
9. NCEP. Summary of Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel II). J Am Med Assoc 1993; 269, 3015–3023.
10. WinkelbyM. A., KraemerH. C., AhnD. K., VaradyA. N.Ethnic and socioeconomic differences in cardiovascular disease risk factors. J Am Med Assoc 1998; 280, 356–362.
11. Joint National Committee on the Detection, Evaluation, and Treatment of Blood Pressure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42, 1206.
12. GueyffierF., BoutitieF., BoisselJ. P., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized controlled trials. Ann Intern Med 1997; 126, 761–767.
13. WalshJ. M. E., PignoneM. Drug treatment of hyperlipidemia in women. J Am Med Assoc 2004; 291, 2243–2252.
14. FordE. S., et al. Serum cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Survey, 1999 to 2000. Circulation 2003; 107, 2185–2189.
15. ManolioT. A., PearsonT. A., WengberN. K., et al. Cholesterol and heart disease in older persons and women. Ann Epidemiol 1992; 2, 161–176.
16. BassK. M., NewschafferC. H., KlagM. J., BushT. L.Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153, 2209–2216.
17. JacobsD. R. Jr., MebanI. L., BangdiwalaS. I., CriquiM. H., TyrolerH. A.High-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinic Prevalence Study. Am J Epidemiol 1990; 131, 32–47.
18. HokansonJ. E., AustinM. A.Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3(2), 213–219.
19. AustinM. A., HokansonJ. E., EdwardsK. L.Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81(4A), 7B–12B.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,538 high-risk individuals: a randomized placebo controlled trial. Lancet 2002; 360, 7–22.
21. NCEP. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III). J Am Med Assoc 2001; 285, 2486–2497.
22. Institute for Clinical Systems Improvement (ICSI). Lipid Management in Adults, Bloomington, MN: ICSI, 2006.
23. WillettW. C., GreenA., StampferM. J., et al. Relative and absolute excess risk of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987; 317, 1303–1309.
24.National Health Interview Survey (NHIS), January–June 2006. Bethesda, MD: National Center for Health Statistics.
25. HansenE. F., AndersenL. T., Von EybenF. E.Cigarette smoking and age at first acute myocardial infarction, and influence of gender and extent of smoking. Am J Cardiol 1993; 71, 1439–1442.
26. RosenbergL., PalmerJ. R., ShapiroS. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322, 213–217.
27. WilsonK., GibsonN., WillanA., CookD. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160(7), 939–944.
28. GeissL. S., HermanW. H., SmithP. J.Mortality in non-insulin-dependent diabetes. In Diabetes in America, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1995, pp. 249–250.
29. MansonJ. E., SpelsbergA. Risk modification in the diabetic patient. In MansonJ. E., RidkerP. M., GazianoJ. M., HennekensC. H., eds., Prevention of Myocardial Infarction, New York: Oxford University Press, 1996, pp. 241–273.
30. GuK., et al. Diabetes and decline in heart disease mortality in US adults. J Am Med Assoc 1999; 281, 1291–1297.
31. Centers for Disease Control and Prevention. The Third National Health and Nutrition Examination Survey (NHANES III 1988–94) Reference Manuals and Reports. Bethesda, MD: National Center for Health Statistics, 1996.
32. HuntK. J., ResendezR. G., WilliamsK., et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110, 1251–1257.
33. KushiL. H., FeeR. M., FolsomA. R., MinkP. J., AndersonK. E., SellersT. A.Physical activity and mortality in postmenopausal women. J Am Med Assoc 1997; 277, 1287–1292.
34. StampferM. J., HuF. B., MansonJ. E., RimmE. B., WillettW. C.Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343, 16–22.
35. National Center for Health Statistics, http://www.cdc.gov/nchs/products/pubs/pubd/hestats/3and4/sedentary.htm, accessed 12/06.
36. BlairS. N., KohlH. W. III, PaffenbargerR. S. Jr., ClarkD. G., CooperK. H., GibbonsL. W.Physical fitness and all-cause mortality; a prospective study of healthy men and women. J Am Med Assoc 1989; 262, 2395–2401.
37. ColditzG. A., CoakleyE. Weight, weight gain, activity, and major illnesses: the Nurses' Health Study. Int J Sports Med 1997; 18(suppl 3), S162–S170.
38. KuczmarskiR. J., FlegalK. M., CampbellS. M., JohnsonC. L.Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. J Am Med Assoc 1994; 272, 205–211.
39. MansonJ. E., StampferM. J., ColditzG. A., et al. A prospective study of obesity and the risk of coronary heart disease in women. N Engl J Med 1990; 322, 882–889.
40. KaplanN. M.The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149, 1514–1520.
41. BjorntorpP. Regional patterns of fat distribution. Ann Intern Med 1985; 103, 994–995.
42. GleimG. W.Exercise is not an effective weight loss modality in women. J Am Coll Nutr 1993; 12, 363–367.
43. GrodsteinF., MansonJ. E., ColditzG. A., WillettW. C., SpeizerF. E., StampferJ. M.A prospective, observational study on hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133, 933–941.
44Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Am Med Assoc 1995; 273, 199–208.
45. HullyS., GradyD., BushT., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280, 605–613.
46.Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288, 321–333.
47. SalpeterS. R., WalshJ. E., GreyberE., SalpeterE. E.Coronary heart disease events associated with hormone therapy in younger and older women, a meta-analysis. J Gen Intern Med 2006; 21(4), 363–366.
48. MoscaL., AppelL. J., BenjaminE. J., et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109, 672–693.
49. ClearfieldM. Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy. Prev Cardiol 2004; 7, 131–136.
50. LiaoJ. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002; 86, 5–18.
51. JonesP. H., DavidsonM. H., SteinE. A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR) trial. Am J Cardiol 2003; 92, 152–160.
52. MoscaL., BankaC. L., BenjaminE. J., et al., for the American Heart Association Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. American Heart Association website, available at http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.
53. The Steering Committee of the Physicians' Health Study Research Group. Final report from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321, 129–135.
54. RidkerP. M., CookM. R., LeeI.-M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13), 1293–1304.
55. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308, 81–106.
56. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2, 349.
57. HarringtonR. A., BeckerR. C., EzekowitzM., et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126, 513S.
58. BraunwaldE., AntmanE., BeasleyJ., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Available at www.acc.org/qualityandscience/clinical/statements.htm, accessed 12/23/06.
59. HaydenM., PignoneM., PhillipsC., MulrowC. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136, 161–172.
60. KrumholzH. M., PhilbinD. M. Jr., WangY., et al. Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina. J Am Coll Cardiol 1998; 31, 957.
61. StaffordR. S.Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000; 101, 1097.
62. StampferM. J., HennekensC. H., MansonJ. E., et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328, 1444.
63. de Gaetano, G.Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357, 89.
64MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360, 23.
65. McCarthyB. C., BeshanskyJ. R., D'AgostinoR. B., SelkerH. P.Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study. Ann Emerg Med 1993; 22, 579–582.
66. PopeJ. H., AufderheideT. P., RuthazerR., WoolardR. H., FeldmanJ. A., BeshankyJ. R., et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342, 1163–1170.
67. GoldbergR., GoffD., CooperL., LuepkerR., ZapkaH., BittnerV., et al. Age and sex differences in presentation of symptoms among patients with acute coronary disease: the REACT trial. Coron Artery Dis 2000; 11, 399–407.
68. MilnerK. A., FunkM., RichardsS., WilmesR. M., VaccarinoV., KrumholzH. M.Gender differences in symptom presentation association with coronary heart disease. Am J Cardiol 1999: 84, 396–399.
69. GoldmanL., CookE. F., BrandD. A., LeeT. H., RouanG. W., WeisbergM. C., et al. A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med 1988; 318, 797–803.
70. SullivanA. K., HoldrightD. R., WrightC. A., et al. Chest pain in women: clinical, investigative, and prognostic features. Br Med J 1994; 308, 883–886.
71. SheiferS. E., CanosM. R., WeinfurtK. P., AroraU. K., MendelsohnF. O., GershB. J., WeissmanN. J.Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J 2000; 139, 649–653.
72. KudenchukP. J., MaynardC., MartinJ. S., WirkusM., WeaverW. D.Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Cardiol 1996; 78, 9–14.
73. PepineC. J.Angina pectoris in a contemporary population: characteristcs and therapeutic implications. TIDES Investigators. Cardiovasc Drugs Ther 1998; 12(Supp 3), 211–216.
74. LegatoM. J.Gender-specific physiology: how real is it? How important is it?Int J fertil 1997; 42(1), 19–29.
75. LightK. C., HerbstM. C., BragdonE. E., HinderliterA. L., KochG. G., DavisM. R., et al. Depression and type A behavior pattern in patients with coronary artery disease: relationships to painful versus silent myocardial ischemia and B-endorphin responses during exercise. Psychosom Med 1991; 53, 669–683.
76. CarneyR. M., BlumenthalJ. A., SteinP. K., WatkinsL., CatellierD., BerkmanL. F., et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104, 2024–2028.
77. AyanianJ. Z., EpsteinA. M.Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med 1991; 325(4), 221–225.
78. RogerV. L., FarkouhM. E., WestonS. A., ReederG. S., JacobsenS. J., ZinsmeisterA. R., et al. Sex differences in evaluation and outcome of unstable angina. J Am Med Assoc 2000; 283(5), 646–652.
79. MehtaR. H., MontoyeC. K., FaulJ., et al. Enhancing quality of care for acute myocardial infarction: shifting the focus of improvement form key indicators to process of care and tool use. J Am Coll Cardiol 2004; 43, 2166–2173.
80. MehtaR. H., MontoyeC. K., GalloglyM., et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. J Am Med Assoc 2002; 287, 1269–1276.
81. RyanT. J., AntmanE. M., BrooksN. H., et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100, 1016–1030.
82. ACC/AHA 2002 Guideline Update for Exercise Testing: a Report of the American College of Cardiology/AHA Task Force on Practice Guidelines. www.americanheart.org.
83. ChaitmanB. R., BourassaM. G., DavisK., et al. Angiographic prevalence of high risk coronary artery disease in patient subsets (CASS). Circulation 1981; 64, 360–367.
84. MillerD. D.Noninvasive diagnosis of CAD in women. J Myocard Ischem 1995; 7, 263–268.
85. SchlantR. C., BlomqvistC. G., BrandenburgR. O., et al. Guidelines for exercise testing: a report of the Joint American College of Cardiology/American Heart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on Exercise Testing). Circulation 1986; 74(3), 653–667A.
86. ClarkP. I., GlasserS. P., LymanG. H., et al. Relation of results of exercise stress tests in young women to phases of the menstrual cycle. Am J Cardiol 1988; 61(1), 197–199.
87. HungJ., ChaitmanB. R., LamJ., et al. Noninvasive diagnostic test choices for the evaluation of coronary artery disease in women: a multivariate comparison of cardiac fluoroscopy, exercise electrocardiography and exercise thallium myocardial perfusion scintigraphy. J Am Coll Cardiol 1984; 4(1), 8–16.
88. MarwickT. H., AndersonT., WilliamsM. J., et al. Exercise echocardiography is an accurate and cost-effective technique for detection of coronary artery disease in women. J Am Coll Cardiol 1995; 26, 335–341.
89. WeinerD. A., RyanT. J., ParsonsL., et al. Long-term prognostic value of exercise testing in men and women from the Coronary Artery Surgery Study (CASS) registry. Am J Cardiol 1995; 75(14), 865–870.
90. PrattC. M., FrancisJ. M., DivineG. W., YoungJ. B.Exercise testing in women with chest pain. Are there additional exerice characteristics that predict true positive test results?Chest 1989; 95, 139–144.
91. MoraS., RedbergR. F., CuiY., WhitemanM. K., FlawsJ. A., SharrettA. R., BlumenthalR. S.Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. J Am Med Assoc 2003; 290, 1600–1607.
92. KaskiJ. C., RosanoG. M. C., CollinsP., NihoyannopoulosP., MaseriA., Poole-WilsonP. A.Cardiac syndrome X: clinical characteristics and left ventricular function. J Am Coll Cardiol 1995; 25, 807–814.
93. VaccarinoV., ParsonsL., EveryN. R., BarronH. V., KrumholzH. M.Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999; 341, 217–225.
94. ChandraN. C., RogersW. J., Tiefenbrunn, A. J., et al. for the National Registry of Myocardial Infarction (NRMI) Investigators. High MI mortality in women: gender or age?JACC 1993; 21(Suppl A), 347A.
95. WeaverW. D., WhiteH. D., WilcoxR. G., et al. Comparisons of characteristics and outcomes among women and men with acute MI treated with thrombolytic therapy. J Am Med Assoc 1996; 275, 777–782.
96. HochmanJ. S., TamisJ. E., ThompsonT. D., et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med 1999; 341, 226–232.
97. O'ConnorG. T., MortonJ. R., DiehlM. J., et al. Differences between men and women in hospital mortality associated with coronary artery bypass graft surgery. Circulation 1993; 88, 2104–2110.
98. VaccarinoV., AbramsonJ. L., VeledarE., et al. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation 2002; 105, 1176–1181.
99. JacobsA. K.Coronary revascularization in women in 2003: sex revisited. Circulation 2003; 107, 375.
100. JacobsA. K., KelseyS. F., BrooksM. M., et al. Better outcome for women compared with men undergoing coronary revascularization a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1998; 98, 1279–1285.
101. JacobsA. K., JohnstonJ. M., HavilandA., et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2002; 39, 1606–1614.
102. ChoL., TopolE. J., BalogC., et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. J Am Coll Cardiol 2000; 36, 381–386.
103. HogueC. W. Jr., BarzilaiB., PieperK. S., et al. Sex differences in neurological outcomes and mortality after cardiac surgery: a Society of Thoracic Surgery National Database report. Circulation 2001; 103, 2133–2137.
104. HerlitzJ., Brandrup-WognsenG., KarlsonB. W., et al. Mortality, risk indicators of death, mode of death and symptoms of angina pectoris during 5 years after coronary artery bypass grafting in men and women. J Intern Med 2000; 247, 500–506.
105. MoriceM.-C., SerruysP. W., SousaJ. E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346, 1173–780.
106. MosesJ. W., LeonM. B., PopmaJ. J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349, 1315–1323.
107. SousaJ. E., CostaM. A., AbizaidA., et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103, 192–195.

References

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, revised edition, 2003. Atlanta, GA: US Departmental of Health and Human Services, Centers for Disease Control and Prevention, 2004.
2. KingH., AubertR. E., HermanW. H.Global burden of diabetes, 1995–2025. Diabetes Care 1998; 21(9), 1414–1431.
3. GuK., CowieC. C., HarrisM. I.Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care 1998; 21(7), 1138–1145.
4. American Diabetes Association. Screening for diabetes. Diabetes Care 2002; 25(S1), S21–S24.
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25(S1), S5–S20.
6. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group, Technical Report Series, no. 726, Geneva: World Health Organization, 1985.
7. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25(S1), S33–S49.
8. American Diabetes Association. Standards of medical care in diabetes – 2006. Diabetes Care 2006; 29(S1), S4–S42.
9. American Diabetes Association and NIDDK. The prevention or delay of type 2 diabetes. Diabetes Care 2002; 25(4), 742–749.
10. ColditzG. A., WillettW. C., RotnitzkyA., MansonJ. E.Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 262(7), 481–486.
11. FolsomA. R., KushiL. H., HongC. P.Physical activity and incident diabetes mellitus in postmenopausal women. Am J Public Health 2000; 90(1), 134–138.
12. KnowlerW. C., Barret-ConnorE., FowlerS. E., HammanR. F., LachinJ. M., WalkerE. A., NathanD. M.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002; 346(6), 393–403.
13. PoirierL., CoburnK. Women and Diabetes, Alexandria, VA: American Diabetes Association, 1997.
14. SamarasK., HaywardC., SullivanD., KellyR., CampbellL. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes. Diabetes Care 1999; 22(9), 1401–1407.
15. MatthewsK. A., MeilahnE., KullerL. H., KelseyS. F., CaggiulaA. W., WingR. R.Menopause and risk factors for coronary heart disease. New Engl J Med 1989; 321, 641–646.
16. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. J Am Med Assoc 1995; 263, 199–208.
17. AnderssonB., MattssonL. A., HahnI., MarinP., LapidusL., HolmG., BengtssonB.-A., BjorntorpP. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes. J Clin Endocrinol Metab 1997; 82, 638–643.
18. StrattonI. M., AdlerA. I., NeilH. A., MatthewsD. R., ManleyS. E., CullC. A., HaddenD., TurnerR. C., HolmanR. R.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321, 405–426.
19. FerraraA., KarterA., AckersonL., LiuJ., SelbyJ. Hormone replacement therapy is associated with better glycaemic control in women with type 2 diabetes. Diabetes Care 2001; 24(7), 1144–1260.
20. HulleyS., GradyD., BushT., FurbergC., HerringtonD., RiggsB., VittinghoffE. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998; 280(7), 605–613.
21. KanayaA. M., HerringtonD., VittinghoffE., LinF., GradyD., BittnerV., CauleyJ. A., Barrett-ConnorE. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement study. Ann Intern Med 2003; 138, 1–9.
22. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002; 288(3), 321–333.
23. MansonJ. E., HsiaJ., JohnsonK. C., RossouwJ. E., AssafA. R., LasserN. L., TrevisanM., BlackH. R., HeckbertS. R., DetranoR., StricklandO. L., WongN. D., CrouseJ. R., SteinE., CushmanM. Estrogen plus progestin and the risk of coronary heart disease. N Eng J Med 2003; 349(6), 523–534.
24. HuF. B., StampferM. J., SolomonC. G., LiuS., WillettW. C., SpeizerF. E., NathanD. M., MansonJ. E. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. Arch Intern Med 2001; 161, 1717–1723.
25. GradyD., HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. J Am Med Assoc 2002; 288(1), 49–57.
26. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement Online, 17(1), 1–36, March 26–29, 2000.
27. SurwitR., Van TilburgM., ZuckerN., McCaskillC., ParekhP., FeinglosM., EdwardsC., WilliamsP., LaneJ. Stress management improves long-term glycemic control in type 2 diabetes. Diabetes Care 2002; 25(1), 30–34.
28. DormanJ., SteenkisteA., FoleyT., StrotmeyerE., BurkeJ., KullerL., KwohC. Menopause in type 1 diabetic women: is it premature? Diabetes 2001; 50, 1857–1862.
29. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002; 25(S1), S50–S60.
30. American Diabetes Association. Diabetes mellitus and exercise. Diabetes Care 2002; 25(S1), S64–S68.
31. DevlinJ. T., RudermanN., eds. The Health Professional's Guide to Diabetes and ExerciseAlexandria VA: American Diabetes Association, 1995.
32. HuF. B., StampferM. J., SolomonC., LiuS., ColditzG. A., SpeizerF. E., WillettW. C., MansonJ. E. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 2001; 134, 96–105.
33. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care 2002; 25(S1), S25–S26.
34. FeinglosM. N., BethelM. A., Treatment of type 2 diabetes mellitus. Med Clinics North Am 1998; 82(4), 757–790.
35. InzucchiS. E., Oral antihyperglycemic therapy for type 2 diabetes, scientific review. J Am Med Assoc 2002; 287(3), 360–372.
36. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329, 977–986.
37. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352, 837–853.
38. KoerbelG., KorytkowskiM. Coronary heart disease in women with diabetes. Diabetes Spectrum 2003; 16(3), 148–263.
39. HowardB., CowanL., GoO., WeltyT., RobbinsD., LeeE. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. Diabetes Care 1998; 21(6), 2658–2665.

Additional references

www.diabetes.org – American Diabetes Association
www.endo-society.org – The Endocrine Society
www.mayoclinic.com – information on diabetes and menopause
www.cdc.gov/diabetes/index.htm – Centers for Disease Control and Prevention, general information on diabetes and links to other diabetes-related websites and resources

References

1. TurnbridgeW. M., EveredD. C., HallR., et al. The spectrum of thyroid disease in a community: the Wickham survey. Clin Endocrinol 1977; 7, 481–493.
2. SawinC. R., CastelliW. P., HershmanJ. P., McNamaraP., BacharachP. The aging thyroid. Thyroid deficiency in the Framingham study. Arch Intern Med 1985; 145, 1386–1388.
3. dos Santos SilvaI., SwerdlowA. J. Sex differences in the risks of hormone-dependent cancers. Am J Epidemiol 1993; 138, 10–28.
4. BoringC. C., SquiresT. S., TongT. Cancer statistics, 1993. CA Cancer J Clin 1993; 43, 7–26.5.
5. ShammaF. N., AbrahamsJ. J. Imaging in endocrine disorders. J Reprod Med 1995; 37, 39–45.
6. FarwellA. P., BravermanL. E. Inflammatory thyroid disorders. Otolaryngol Clin North Am 1996; 29, 541–556.
7. GusseklooJ., van ExelE., deCraenA. J. M., et al. Thyroid status, disability and cognitive function, and survival in old age. J Am Med Assoc 2004; 292, 2591–2599.
8. AACE/AME Task Force on Thyroid Nodules. Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocrine Pract 2006; 12, 63–102.

References

1. VasanR. S., BeiserA., SeshadriS., et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. J Am Med Assoc 2002; 287, 1003–1010.
2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report AMA, 2003, 289, doi:10.1001/jama.289.19.2560. http://jamaama/assn.org/cgi/content/full/289.19.2560v1, accessed 3/10/07.
3. LewingtonS., ClarkeR., QizilbashN., PetoR., CollinsR. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002; 360, 1903–1913.
4. BurtV. L., WheltonP., RoccellaE. J., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25, 305–313.
5. RobbinsM. A., EliasM. P., CroogS. H., ColtonT. Unmediated blood pressure levels and quality of life in elderly hypertensive women. Psychosoc Med 1994; 56, 251–259.
6. GueyfferF., BournieF., BoisselJ. P., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in men and women. Ann Intern Med 1997; 125, 761–767.
7. RouxO., ChapellierM., CzernichowS., Nisse-DurgeatS., SafarM. E., BlacherJ. Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Press 2006; 15(1), 6–13.
8. GeleijinseJ. M., WettermanJ. C., BakA. A., BreijenJ. H., GrobeeD. E.Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderated hypertension. Br Med J 1994; 309, 436–440.
9. DickinsonH. O., MasonJ. M., Nicolson. D. J., et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertension 2006; 24(2), 215–233.
10. SchillaciG., PasqualiniL., VaudoG.Effect of body weight changes on 24-hour blood pressure and left ventricular mass in hypertension: a 4-year follow-up. Am J Hypertension 2003; 16(8), 634–639.
11. KelleyG. A. Aerobic exercise and resting blood pressure among women: a meta-analysis. Prev Med 1999; 28, 264–275.
12. FagardR. H. Exercise is good for your blood pressure: effects of endurance training and resistance trainingClin Exp Pharmacol Physiol 2006; 33(9), 853–856.
13. CroogS. H., EliasM. F., CoiltonT. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertension 1994; 7, 329–339.
14. Agabiti-RoseiE., AmbrosinioneE., PireeliA., StimpelM., ZanchettiA. Efficacy and tolerability of noexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Eur J Clin Pharmacol 1999; 545, 185–189.
15. FitzpatrickA. I., DalingJ. R., FurbergC. D., KronmalR. A., WeissfeldJ. L.Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997; 80, 1438–1447.
16. FryzekJ. P., PoulsenA. H., LipworthL., PedersenL., NorgaardM., McLaughlinJ. K., FriisS. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 2006; 97(3), 231–236.
17. GueyffierF., BulpittC., BoisselJ. P., SchronE., EkbomT., FagardR., et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDIANA Group. Lancet 1999; 353, 793–796.
18. WingL. M., ReidC. M., RyanP., BeilinL. J., BrownM. A., JenningsG. L., et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348, 583–592.
19. RosenfeldJ. A. Hypertension occurring postpartum for the first time postpartum: was it preeclampsia. Tenn Med J 1992; 85, 465–466.
20. LandisS. H., MurrayT., BoldenS., WingoP. A.Cancer statistics 1999. CA Cancer J Clin 1999; 49, 8–31.
21. Agency for Health Care Policy and Research Clinical Practice Guidelines. Post stroke rehabilitations. Assessment, referral and patient management. Am Fam Physician 1995; 82, 461–470.
22. AyalaC., CroftJ. B., GreenlundK. J., et al. Sex differences in US mortality rates for stroke and stroke subtypes by race/ethnicity and age, 1995–1998. Stroke 2002; 33(5), 1197–1201.
23. VartianenE., SartiC., TuomitehtoJ., KuulasmaaK. Do changes in cardiovascular risk factors explain changes in mortality from stroke in Finland?Br Med J 1995; 310, 901–904.
24. ShuaihA., BoyleC. Stroke in the elderly. Curr Opin Neurol 1994; 7, 41–47.
25. SuriM. F., ZhouJ., DivaniA. A., Qureshi A. I. African American women have poor long-term survival following ischemic stroke. Neurology 2006; 67(9), 1623–1629.
26. MoreyS. S.National Stroke Association develops consensus statement on prevention of stroke. Am Fam Physician 1999; 99, 463–467.
27. EnglishK. M., ChannerK. S.Managing atrial fibrillation in elderly people. Br Med J 1999; 318, 1088–1089.
28. BenjaminE. J., LevyD., VaziriS. M., et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. J Am Med Assoc 1994; 271, 840–844.
29. FribergJ., ScharlingH., GadsbollN., et al. Sex-specific increase in the prevalence of atrial fibrillation (the Copenhagen City Heart Study). Am J Cardiol 2003; 92, 1419–1423.
30. HartR. G., ShermanD. G., EastonJ. D., CairnsJ. A.Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998; 51, 674–681.
31. AlbersG. Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994; 154, 1443–1457.
32. The Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. The stroke Prevention in Atrial Fibrillation Trial II. Lancet 1994; 344, 1383–1389.
33. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84, 527–539.
34. RedgraveJ. N., RothwellP. M. Asymptomatic carotid stenosis: what to do. Curr Opin Neurol 2007; 20(1), 58–64.
35. HellingsW. E., PasterkampG., VerhoevenB. A., et al. Gender-associated differences in plaque phenotype of patients undergoing carotid end arterectomy. J Vasc Surg 2007; 45(2), 289–296; discussion 296–297.
36. ColditzG. A., BonitaR., StampferM. I., et al. Cigarette smoking and risk of stroke in middle aged women. N Engl J Med 1988; 318, 937–941.
37. HillM. D., YiannakouliasN., JeerakathilT., TuJ. V., SvensonL. W., SchopflocherD. P. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004; 62, 2015–2020.
38. KerberK. A., BrownD. L., LisabethL. D., SmithM. A., MorgensternL. B.Stroke among patients with dizziness, vertigo, and imbalance in the emergency department: a population-based study. Stroke 2006; 37(10), 2484–2487.
39.Data from KleindorferD., PanagosP., PancioliA., et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005; 36(4), 720–723.
40. BarrJ., McKinleyS., O'BrienE., HerkesG. Patient recognition of and response to symptoms of TIA or stroke. Neuroepidemiology 2006; 26(3), 168–175.
41. TanneD., Koren-MoragN., GoldbourtU. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke 2004; 35(10), 2351–2355.
42. TanneD., Koren-MoragN., GraffE., GoldbourtU. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 2001; 104(24), 2892–2897.
43. GorelickP., SechenovaO., HennekensC. H. Evolving perspectives on clopidogrel in the treatment of ischemic stroke. J Cardiovasc Pharmacol Ther 2006; 11(4), 245–248.
44. Leonardi-BeeJ., BathP. M., BousserM. G., et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36(1), 162–168.
45. PrejbiszA., KabatM., JanuszewiczA., et al. Characterization of insomnia in patients with essential hypertension. Arch Intern Med 2006; 15(4), 213–219.

References

1. CompstonJ. E., CooperC., KanisJ. A.Bone densitometry in clinical practice. Br Med J 1995; 310, 507–510.
2. BellatoniM. F.Osteoporosis and treatment. Am Fam Physician 1996; 54, 986–996.
3. CummingsS. F., NevittM. C., BrownerW. S., et al. Risk factors for hip fractures in white women. A prospective study. N Engl J Med 1995; 332, 767–771.
4. CompstonJ. E.Risk factors for osteoporosis. Clin Endocrinol 1992; 36, 223–224.
5. EnsrudK. E., CauleyJ., LipschutzR., CummingsS. R.Weight change and fractures in older women. Ann Intern Med 1997; 157, 857–861.
6. North American Menopause Society. The role of calcium in peri- and postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 2006; 13(6), 862–877; quiz 878–880.
7. JacksonR. D., LaCroixA. Z., GassM.Women's Health Initiative Investigators. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. N Engl J Med 2006; 354(7), 669–683.
8. MalabananA. O., HolickM. F.Vitamin D and bone health in postmenopausal women. J Womens Health (Larchmt) 2003; 12(2), 151–156.
9. EttingerB., BlackD. M., MidalB. H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3 year randomized clinical trial. J Am Med Assoc 1999; 282, 637–642.
10. LibermanU. A., WeissS. R., BrollJ.et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333, 1437–1443.
11. BlackD. M., CummingsS. R., KarpfD. B., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348, 1535–1541.

References

1. Centers for Disease Control and Prevention (CDC). National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions – United States, 2003. MMWR Morb Mortal Wkly Rep 2007; 56(1), 4–7.
2. DillonC. F., HirschR., RaschE. K., GuQ.Symptomatic hand osteoarthritis in the United States: prevalence and functional impairment estimates from the third U. S. National Health and Nutrition Examination Survey, 1991–1994. Am J Phys Med Rehabil 2007; 86(1), 12–21.
3. DillonC. F., RaschE. K., GuQ., HirschR.Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991–94. J Rheumatol 2006; 33(11), 2271–2279.
4. ChristmasC., CrespoC. J., FranckowiakS. C., BathonJ. M., BartlettS. J., AndersenR. E. How common is hip pain among older adults? Results from the Third National Health and Nutrition Examination Survey. J Fam Pract 2002; 51(4), 345–348.
5. OstchegaY., HarrisT. B., HirschR., ParsonsV. L., KingtonR. The prevalence of functional limitations and disability in older persons in the US: data from the National Health and Nutrition Examination Survey III. J Am Geriatr Soc 2000; 48(9), 1132–1135.
6. FelsonD. T., ZhangY., AnthonyI. M., NimarkA., AndersonH. Weight loss reduces the risk of symptomatic knee osteoarthritis in women: The Framingham Study. Ann Intern Med 1992; 116, 535–539.
7. SzoekeC., DennersteinL., GuthrieJ., ClarkM., CicuttiniF.The relationship between prospectively assessed body weight and physical activity and prevalence of radiological knee osteoarthritis in postmenopausal women. J Rheumatol 2006; 33(9), 1835–1840.
8. SilmanA. J., NewmanJ.Obstetric and gynecological factors in susceptibility to peripheral joint osteoarthritis. Ann Rheum Dis 1996; 55, 671–673.
9. NevittM. C., FelsonD. T.Sex hormones and the risk of osteoarthritis in women. Epidemiologic evidence. Ann Rheum Dis 1996; 55, 673–676.
10. SzoekeC. E., CicuttiniF. M., GuthrieJ. R., ClarkM. S., DennersteinL.Factors affecting the prevalence of osteoarthritis in healthy middle-aged women: data from the longitudinal Melbourne Women's Midlife Health Project. Bone 2006; 39(5), 1149–1155.
11. BarlowJ. H., TurnerA. P., WrightyC. C.Long term outcomes of an arthritis self-management programme. Br J Rheumatol 1998; 37, 1315–1319.
12. Herrero-BeaumontG., IvorraJ. A., Del Carmen TrabadoM., et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007; 56(2), 555–567.
13. CleggD. O., RedaD. J., HarrisC. L., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354(8), 795–808.
14. MatsumotoA. K. Rheumatoid Arthritis Clinical Presentation. Johns Hopkins Arthritis, http://www.hopkinsarthritis.org/rheumatoid/rheum_clin_pres.html, accessed 3/15/07.
15. JorgensenC., PicotM. C., BolognaC., SanyJ.Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis 1996; 55, 94–98.
16. Van der BinkH. R., Van EverdingenA. A., Van WijkM. J. G., JacobsJ. W. G., BijlsmaJ. W.Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis. Ann Rheum Dis 1993; 52, 862–865.
17. ForslindK., HafstromI., AhlmenM., SvenssonB.The BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis. Ann Rheum Dis 2007; 66(1), 46–52.
18. AbyadA., BoyerJ. T.Arthritis and aging. Curr Opin Rheum 1992; 4, 153–156.
19. NordermarR., EkblomB., ZachrissonI., LundquistK.Physical training in rheumatoid arthritis: a long term study. Scan J Rheumatol 1981; 10, 25–30.
20. de JongZ., MunnekeM., ZwindermanA. H., et al. Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 2003; 48(9), 2415–2424.
21. MottonenT., HannonenP., KorpelaM., et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46(4), 894–898.
22. CallahanL. F., RaoJ., BoutaughM.Arthritis and women's health. Prevalence, impact and prevention. Am J Prev Med 1996; 12, 400–407.
23. SchiffM. H., YuE. B., WeinblattM. E., et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 2006; 23(2), 167–178.
24. BaumgartnerS. W., FleischmannR. M., MorelandL. W., SchiffM. H., MarkensonJ., WhitmoreJ. B. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 2004; 31(8), 1532–1537.
25. LittleC. V., ParsonsT.Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev 2007; 1.
26. HanA., JuddM. G., RobinsonV. A., TaixiangW., TugwellP., WellsG.Tai chi for treating rheumatoid arthritis. Cochrane Database Syst Rev 2007; 1.